- Stock price (Oct 8 2025): CRISPR Therapeutics AG (NASDAQ: CRSP) closed at ~$77.7 per share on 8 Oct 2025. AAII data show that the stock traded between $70.77 and $78.38 during the session, ending the day up about 10 % from the previous close. INDmoney’s live quote recorded a $77.77 price at 22:36 IST (Oct 8 2025), with a daily range of $70.77–$78.38 and a 52‑week range of $30.04–$73.95 [1].
- Recent performance: CRSP shares have surged lately. Simply Wall St notes that the stock rallied 38.3 % over the previous month and delivered ~62 % return over the past year [2]. The Motley Fool highlighted that CRSP was up ~10 % during trading on 8 Oct 2025.
- Market cap and liquidity: The company’s market capitalization was about $6.2 billion with roughly 87 million shares outstanding [3]. Trading volume reached 3.1 million shares on 8 Oct 2025 [4].
- Analyst consensus: Fintel data show that analysts’ one‑year price target averages about $81 per share, with forecasts ranging from $32 to $281 [5]. Directorstalk reports 15 buy ratings, 10 holds and one sell, implying bullish sentiment and a potential 15–27 % upside [6].
- Financial position: CRISPR Therapeutics remains pre‑profit. In Q2 2025 it reported revenue of $0.9 million, research and development (R&D) expenses of $69.9 million and a net loss of $208.5 million [7]. Cash and marketable securities totaled ~$1.72 billion, providing runway for clinical programs [8]. Q1 2025 results showed a net loss of $136 million with cash and securities of $1.86 billion [9] [10].
Stock Price, Volume and Sentiment
According to AAII, CRSP’s share price on 8 Oct 2025 closed at $77.727, up 10.06 % from the previous close. The stock traded between $70.77 and $78.38 that day and has risen ~20 % during October. Over the prior year the share price ranged from $30.04 to $73.95, and year‑to‑date performance stood at +97.5 %. Trading volume on INDmoney’s quote was 3.1 million shares [11].
Fintel’s data as of 7 Oct 2025 list a market cap of roughly $6.2 billion, a beta of 1.32 and a short interest of 26.3 %, suggesting significant volatility and short‑seller interest [12]. The average one‑year price target of $81.3 implies modest upside relative to the Oct 8 close [13]. Directorstalk’s technical analysis notes that the 50‑day moving average (~$58) is above the 200‑day (~$46) and the relative‑strength index (RSI) near 60, reflecting bullish momentum [14]. AAII’s momentum grade (four‑quarter relative strength of 10.38 % and momentum score of 80) also classifies the stock as strong momentum.
News and Developments (late Sep – Oct 8 2025)
Product and clinical progress
- SyNTase gene‑editing technology: On 1 Oct 2025, CRISPR Therapeutics announced that its SyNTase platform, which combines a compact Cas9 nuclease with an engineered polymerase for site‑specific gene correction, would be highlighted at the European Society of Gene and Cell Therapy (ESGCT) congress. Pre‑clinical data showed >95 % correction of the SERPINA1 E342K mutation in hepatocyte models and >70 % mRNA correction with three‑fold increase in serum alpha‑1 antitrypsin in a humanized rat model [15]. The technology demonstrated high efficiency and low off‑target effects, supporting a potential curative therapy for alpha‑1 antitrypsin deficiency (AATD) [16].
- Phase 2 trial of SRSD107: On 22 Sep 2025, the company and partner Sirius Therapeutics dosed the first patient in a Phase 2 trial of SRSD107, a small‑interfering RNA (siRNA) designed to reduce Factor XI levels and prevent venous thromboembolism in orthopedic surgery. Phase 1 results showed >93 % reduction in FXI with responses lasting up to six months [17]. CRISPR will co‑develop and commercialize SRSD107 with Sirius, leading U.S. commercialization, highlighting its diversification beyond gene editing [18].
- Lipid‑nanoparticle in‑vivo programs: On 9 Sep 2025, CRISPR announced that CTX310 (ANGPTL3‑targeting therapy) would be featured as a late‑breaking presentation at the American Heart Association Scientific Sessions. CTX310, delivered via lipid nanoparticles, is designed to reduce triglycerides and LDL cholesterol. The company also presented pre‑clinical data for CTX340 (targeting angiotensinogen for refractory hypertension). CRISPR is studying CTX310 and CTX320 (targeting lipoprotein (a)) in ongoing trials, while CTX450 (aimed at ALAS1 for acute hepatic porphyria) remains in pre‑clinical development [19].
- Q2 2025 results and pipeline update: In the Aug 2025 earnings release, CEO Samarth Kulkarni said that momentum for CASGEVY was building with over 75 authorized treatment centers and 115 patients having completed cell collection, and that early CTX310 data showed up to 82 % reduction in triglycerides and 86 % reduction in LDL [20]. The company expects additional CTX320 data in early 2026 and updates on immuno‑oncology candidates CTX112 and CTX131 [21].
- Recognition and other news: In June 2025, CRISPR was named to TIME’s 100 Most Influential Companies list, recognized for pioneering gene‑editing medicine across hemoglobinopathies, cardiovascular and autoimmune diseases. CEO Kulkarni said the company’s mission is “to transform medicine through bold science and innovation” [22]. TIME editors noted that nominees were evaluated on impact, innovation, ambition and success [23].
Regulatory and access updates
- Texas Medicaid coverage: On 1 Oct 2025, the Texas Medicaid & Healthcare Partnership updated prior‑authorization criteria for CASGEVY (exagamglogene autotemcel). CASGEVY remains a benefit but now allows confirmation of sickle‑cell disease diagnosis via provider attestation, removes the requirement that patients lack a matched donor, and requires patients to have an inadequate response or contraindication to hydroxyurea [24]. Clients must still be at least 12 years old and have a history of vaso‑occlusive crises [25].
- Enlaza–Vertex collaboration (conditioning): On 2 Sep 2025, Vertex (CRISPR’s Casgevy collaborator) and Enlaza Therapeutics announced a multi‑target collaboration to develop “War‑Lock” protein degradation technology to create small‑format antibody–drug conjugates for gentler conditioning in sickle‑cell and beta‑thalassemia gene therapy. Vertex’s head of research Mark Bunnage said the goal is to develop less toxic conditioning for CASGEVY using Enlaza’s platform and the deal could exceed $2 billion in milestones [26]. Better conditioning could improve patient eligibility and uptake.
Analyst commentary and market sentiment
- Motley Fool / Mitrade: A piece replicated on Mitrade emphasised that while CASGEVY currently has a limited market footprint (around 60,000 eligible patients globally), its price tag of $2.2 million per patient and Vertex’s revenue from early sales suggest it could become a blockbuster. The article highlighted CRISPR’s shift toward in‑vivo therapies (CTX310/CTX320), which are simpler and could address large populations, potentially providing “even more upside” as they progress [27]. It cautioned that regulatory and reimbursement decisions remain key.
- Simply Wall St (Oct 5 2025): The investment site noted that the SyNTase announcement underscores CRISPR’s innovative capability and could act as a near‑term catalyst, but warned that the company is still unprofitable and faces execution risk. It observed that positive pre‑clinical results broaden the pipeline but the long timeline to profitability and capital needs remain concerns [28]. Simply Wall St’s discounted cash flow model valued CRSP at $134.16 per share, implying the stock was 45.7 % undervalued, and its price‑to‑book analysis suggested the current multiple is “about right” [29].
- Directorstalk analysis: Directorstalk reported that analysts set an average price target of ~$81 with 15 buy, 10 hold and one sell ratings [30]. It noted revenue growth of 72.5 % but negative earnings per share and return on equity, reflecting that CRISPR is still investing heavily. Technical indicators such as the 50‑day moving average of $58.05, 200‑day average of $46.51, RSI of 58.57 and MACD above the signal line were interpreted as signs of bullish momentum. Another article by the same outlet highlighted the wide price‑target range ($32–$268) and reiterated the strong buy rating [31].
- AAII assessment: The AAII article categorised CRSP as “Ultra Expensive” based on its value grade, noting that the company’s trailing earnings per share are negative. It emphasised that investors should look beyond price and consider fundamentals; the site assigned a strong momentum score (80) owing to the stock’s outperformance.
Financial Performance and Valuation
Q2 2025 results
CRISPR’s Q2 2025 earnings release reported $0.9 million in revenue, primarily from collaboration agreements, and $69.9 million in R&D expenses [32]. An in‑process R&D charge of $96.3 million related to intangible assets from its collaboration with Capsida drove total operating expenses to $230.2 million [33]. The quarter ended with a net loss of $208.5 million and cash and marketable securities of ~$1.72 billion, giving a runway into 2027 [34].
Q1 2025 results
During Q1 2025, CRISPR recorded a net loss of $136.0 million on $0.6 million in revenue [35]. R&D expenses were $67.9 million, while general and administrative expenses were $19.5 million [36]. Cash, cash equivalents and marketable securities totaled $1.86 billion, giving the company considerable liquidity [37]. These results illustrate heavy investment ahead of potential product launches.
Valuation
CRISPR remains unprofitable, so traditional price‑to‑earnings ratios are not meaningful. Simply Wall St’s discounted‑cash‑flow analysis estimated an intrinsic value of $134.16 per share, implying the stock is ~46 % undervalued [38]. The site’s price‑to‑book comparison placed the company slightly above the biotech industry average but below direct peers, suggesting the current valuation is fair for its risk profile [39]. Fintel’s average price target of $81 corroborates a moderate upside [40], while AAII’s Ultra Expensive rating reflects caution given negative earnings.
Technical Analysis
- Momentum: CRSP shares have exhibited strong momentum. The 50‑day moving average ($58) has crossed above the 200‑day ($46), a bullish “golden cross,” and the RSI around 60 indicates neither overbought nor oversold conditions [41]. The MACD remains above its signal line. AAII’s momentum score of 80 also characterises the stock as strong momentum.
- Volatility & short interest: Fintel lists a beta of 1.32 and short float of 26.3 % [42], suggesting the stock can swing more than the broader market and is a favorite of short sellers. Investors should therefore expect significant volatility around data readouts and regulatory events.
Competitor and Market Landscape
The gene‑editing and gene‑therapy fields are rapidly expanding. A GlobeNewswire report estimated that the global gene‑therapy market will grow from $11.4 billion in 2025 to $58.87 billion by 2034 (20 % CAGR) [43], with in‑vivo therapies dominating the market [44]. This macro trend benefits innovators like CRISPR Therapeutics.
Among competitors:
- Vertex/Enlaza partnership: Vertex has partnered with Enlaza to develop small‑format antibody–drug conjugates aimed at gentler conditioning for Casgevy and future gene therapies, a program that could yield over $2 billion in milestone payments [45].
- UniQure’s Huntington’s gene therapy: On 24 Sep 2025, UniQure reported positive topline results from its pivotal study of AMT‑130 for Huntington’s disease, showing 75 % slowing of disease progression and plans for a BLA filing in early 2026 [46] [47]. The study’s success underscores growing competition in the gene‑therapy space and may raise investor expectations for CRISPR’s own programs.
- Other gene and cell therapy updates: CGTLive’s roundup on 1 Oct 2025 highlighted that Takeda decided to jettison its cell‑therapy programs, while Mavrix Bio’s Angelman syndrome gene therapy MVX‑220 received FDA fast‑track status [48]. The article also noted the FDA issuing new draft guidance documents for gene‑therapy development [49]. These developments illustrate both increasing regulatory engagement and competitive churn.
Short‑ and Long‑Term Outlook
Short term (3–12 months). CRSP’s near‑term performance will be driven by CASGEVY uptake, additional CTX310/320 clinical data, and SyNTase pre‑clinical results. Expanded Medicaid coverage (e.g., Texas) and gentler conditioning could accelerate adoption. Analysts’ consensus of roughly $81 per share suggests limited upside after the October rally [50]. Technical indicators show bullish momentum but high volatility and a large short interest warrant caution [51].
Long term (beyond 2026). CRISPR’s valuation hinges on the success of its diversified pipeline. CASGEVY addresses a patient population of roughly 60,000 and, at $2.2 million per therapy, could achieve blockbuster status [52]. The in‑vivo programs CTX310 and CTX320 target cardiovascular risk factors affecting tens of millions of people [53]; positive data could dramatically expand the company’s addressable market. SyNTase may open the door to curative gene correction for AATD and other diseases [54]. Yet, the company remains unprofitable and faces execution, regulatory and reimbursement risks [55]. Long‑term investors must weigh potential breakthroughs against capital requirements and competition.
Conclusion
CRISPR Therapeutics enters late 2025 as one of the most watched gene‑editing stocks. The 10 % jump on 8 Oct 2025 reflects excitement around novel platforms like SyNTase and the prospect of CASGEVY becoming a blockbuster. However, the company is still burning cash, and earnings remain far on the horizon. Analyst price targets cluster around $81, with some models suggesting significant upside and others urging caution. Investors should follow upcoming clinical readouts, regulatory decisions and partnership developments. With gene‑therapy market growth projected to accelerate and CRISPR’s pipeline spanning hemoglobinopathies, cardiovascular diseases, immuno‑oncology and more, the stock offers both high potential rewards and substantial risks.
References
1. www.indmoney.com, 2. simplywall.st, 3. fintel.io, 4. www.indmoney.com, 5. fintel.io, 6. www.directorstalkinterviews.com, 7. ir.crisprtx.com, 8. ir.crisprtx.com, 9. crisprtx.com, 10. crisprtx.com, 11. www.indmoney.com, 12. fintel.io, 13. fintel.io, 14. www.directorstalkinterviews.com, 15. crisprtx.com, 16. crisprtx.com, 17. crisprtx.com, 18. crisprtx.com, 19. crisprtx.com, 20. ir.crisprtx.com, 21. www.1stoncology.com, 22. ir.crisprtx.com, 23. ir.crisprtx.com, 24. www.tmhp.com, 25. www.tmhp.com, 26. enlazatx.com, 27. www.mitrade.com, 28. simplywall.st, 29. simplywall.st, 30. www.directorstalkinterviews.com, 31. www.directorstalkinterviews.com, 32. ir.crisprtx.com, 33. ir.crisprtx.com, 34. ir.crisprtx.com, 35. crisprtx.com, 36. crisprtx.com, 37. crisprtx.com, 38. simplywall.st, 39. simplywall.st, 40. fintel.io, 41. www.directorstalkinterviews.com, 42. fintel.io, 43. www.globenewswire.com, 44. www.globenewswire.com, 45. enlazatx.com, 46. uniqure.gcs-web.com, 47. uniqure.gcs-web.com, 48. www.cgtlive.com, 49. www.cgtlive.com, 50. fintel.io, 51. fintel.io, 52. www.mitrade.com, 53. www.mitrade.com, 54. crisprtx.com, 55. simplywall.st
